JP Morgan Chase’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
SCM
FLAM
O
DCM
AC
JP Morgan Chase's NPCE Position: Q2 2026 in Review
JP Morgan Chase increased its Neuropace (NPCE) stake by 23% in Q2 2026, buying an estimated $518K and bringing the position to 173,311 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3914.
JP Morgan Chase first reported a position in NPCE in Q2 2021 and has held it in 15 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.
- JP Morgan Chase held 173,311 shares of Neuropace worth $2.86M as of Q2 2026.
- JP Morgan Chase bought 32,170 Neuropace shares in Q2 2026, an estimated $518K.
- Neuropace made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3914 holding.
- JP Morgan Chase first reported a position in Neuropace in Q2 2021 and has held it in 15 quarters since.
- 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.